NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Highlights Comprehensively profile the tumor, exome-wide Combined with ImmunoID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance Profile with ImmunoID NeXT, Monitor with NeXT Liquid Biopsy Leverage somatic variant [...]
Personalis NeXT Dx™ Test Increasingly, oncologists and pathologists are utilizing information on genomic alterations in solid tumors, such as lung, colon, breast, melanoma, and prostate cancers, to help guide and optimize therapeutic options for patients including enrolling into cancer clinical trials. The Personalis NeXT Dx™ Test provides clinicians with a comprehensive [...]
RepertoireID An analytical module of the ImmunoID NeXT Platform Comprehensive Profiling of the TCR Repertoire RepertoireID, an analytics module of the ImmunoID NeXT Platform, enables the detection and analysis of the top TCRα and TCRβ clonotypes in the TCR repertoire found in the tumor microenvironment (TME) of patients’ tumors. [...]
NeoantigenID™ An analytical module of the ImmunoID NeXT PlatformTM Comprehensive Identification of Putative Neoantigens Neoantigens are mutated peptides that are expressed by tumor cells, but not by normal tissue. As a result, they can be recognized as foreign antigens by cells of the immune system — making them promising [...]
ImmunogenomicsID An analytical module of the ImmunoID NeXT PlatformTM Comprehensive Immunogenomic Characterization ImmunogenomicsIDTM, an analytical module of the ImmunoID NeXT Platform, characterizes critical areas of tumor and immune biology such as the antigen processing machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, tumor escape mechanisms, the adaptive and innate [...]
NeoantigenID™ Comprehensive identification of putative neoantigens Neoantigens are mutated peptides that are expressed by tumor cells, but not by normal tissue. As a result, they can be recognized as foreign antigens by cells of the immune system — making them promising targets for personalized cancer immunotherapies such as vaccines [...]
ImmunogenomicsID™ Comprehensive immunogenomic characterization ImmunogenomicsID™, the latest analytics component of the ACE ImmunoID platform, summarizes critical areas of tumor biology such as the antigen processing machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, and tumor escape. ImmunogenomicsID combines exome and transcriptome sequencing data from a paired tumor and normal [...]
